Table 1.
Author | Dose distribution | Cumulative response (%) | Genotype |
n |
|||
KIT | Exon 11 | Exon 9 | WT | ||||
Debiec-Rychter et al[14], 2006 | 400 mg/800 mg | 56 | Exon 11, 9, 13, 17 | 315 | 248 | 58 | 52 |
WT | |||||||
Wardelmann et al[15], 2006 | NA | 50 | Exon 11, 9 | 29 | 22 | 7 | 3 |
WT | |||||||
Yeh et al[16], 2007 | 400 mg | 52 | Exon 11, 9 | 49 | 40 | 9 | 5 |
WT | |||||||
Rutkowski et al[17], 2007 | 400 mg/800 mg | 63 | Exon 11, 9, 13, 17 | 63 | 52 | 9 | 19 |
WT | |||||||
Heinrich et al[18], 2008 | 400 mg/800 mg | 56 | Exon 11, 9, 8, 13, 17 | 325 | 283 | 32 | 67 |
WT |
WT: Wide type; NA: Not available.